A comparison of the neuropathological effects of vigabatrin and carbamazepine in patients with newly diagnosed localization-related epilepsy using MR-based cerebral T2 relaxation time measurements

Epilepsy Research

Volumn 29, Issue 2, 1998, Pages 155-160

  Van Paesschen, W ^a,b   Duncan, J S ^a   Connelly, A ^b  

^a Epilepsy Research Group   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Carbamazepine; Epilepsy; Quantitative MRI; T2 relaxation time; Vigabatrin

Indexed keywords

CARBAMAZEPINE; PLACEBO; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; MALE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; ANTICONVULSANTS; BRAIN; BRAIN MAPPING; CARBAMAZEPINE; CEREBELLUM; EPILEPSY; FEMALE; FRONTAL LOBE; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; VIGABATRIN;

EID: 0031983270     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(97)00077-6     Document Type: Article

References (29)

1. Agosti R, Yasargil G, Egli M, Wieser HG, Wiestler OD Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles. Epilepsy Res. 6:1990;166-170.
2. Arezzo JC, Schroeder CE, Litwak MS, Steward DL Effects of vigabatrin on evoked potentials in dogs. Br J Clin Pharmacol. 27(Suppl 1):1989;S53-60.
3. Butler WH The neuropathology of vigabatrin. Epilepsia. 30(Suppl 3):1989;S15-17.
4. Butler WH, Ford GP, Newberne JW A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol. 15:1987;143-148.
5. Cannon DJ, Butler WH, Mumford JP, Lewis PJ. Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol 1991; Suppl 2:S17-24.
6. Cocito L, Maffini M, Loeb C MRI findings in epileptic patients on vigabatrin for more than 5 years. Seizure. 1:1992;163-165.
7. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
8. Cosi V, Callieco R, Galimberti CA, Manni R, Tartara A, Mumford J, Perucca E Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol. 27(Suppl 1):1989;S61-68.
9. Dodrill CB, Arnett JL, Sommerville KW, Sussman NM Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology. 43:1993;2501-2507.
10. French JA, Mosier M, Walker S, Sommerville K, Sussman N A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology. 46:1996;54-61.
11. Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, Newberne JW Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol. 18:1990;225-238.
12. Graham D Neuropathology of vigabatrin. Br J Clin Pharmacol. 27(Suppl 1):1989;S43-45.
13. Grünewald RA, Thompson PJ, Corcoran R, Corden Z, Jackson GD, Duncan JS Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatry. 57:1994;1057-1063.
14. Hammond EJ, Ballinger WE Jr., Lu L, Wilder BJ, Uthman BM, Reid SA Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy. Epilepsy Res. 12:1992;261-265.
15. Hammond EJ, Rangel RJ, Wilder BJ. Evoked potential monitoring of vigabatrin patients. Br J Clin Pract Symp Suppl 1988;61:S16-23.
16. Hammond EJ, Wilder BJ Effect of gamma-vinyl GABA on human pattern evoked visual potentials. Neurology. 35:1985;1801-1803.
17. Jackson GD, Connelly A, Duncan JS, Grünewald RA, Gadian DG Detection of hippocampal pathology in intractable partial epilepsy: increased sensitivity with quantitative magnetic resonance T2 relaxometry. Neurology. 43:1993;1793-1799.
18. Jackson GD, Grünewald RA, Connelly A, Duncan JS Quantitative MR relaxometry study of effects of vigabatrin on the brains of patients with epilepsy. Epilepsy Res. 18:1994;127-137.
19. Jackson GD, Williams SR, Weller RO, van Buggen N, Preece NE, Williams SC, Butler WH, Duncan JS Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res. 18:1994;57-66.
20. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ Sr. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol. 52:1995;989-996.
21. Liegeois Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients. Epilepsia. 30(Suppl 3):1989;S23-25.
22. Norusis MJ. SPSS for Windows: Base System User's Guide, Release 6. USA:SPSS Inc. 1993.
23. Pedersen B, Hojgaard K, Dam M Vigabatrin: no microvacuoles in a human brain. Epilepsy Res. 1:1987;74-76.
24. Peyster RG, Sussman NM, Hershey BLet al. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia. 36:1995;93-100.
25. Sander JW, Trevisol Bittencourt PC, Hart YM, Shorvon SD Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. J Neurol Neurosurg Psychiatry. 53:1990;1008-1010.
26. Schechter PJ Clinical pharmacology of vigabatrin. Br J Clin Pharmacol. 27(Suppl 1):1989;S19-22.
27. Van Paesschen W, Revesz T, Duncan JS, King MD, Connelly A. Quantitative neuropathology and quantitative magnetic resonance imaging of the hippocampus in temporal lobe epilepsy. Ann Neurol 1997;42:756-66.
28. Weiss KL, Schroeder CE, Kastin SJet al. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology. 44:1994;1944-1949.
29. Yarrington JT, Gibson JP, Dillberger JEet al. Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol. 21:1993;480-489.